aca24@aca-pharma.de/ +49 341 223 292 36

REF-15 introduced

Kommentare deaktiviert für REF-15 introduced

In 2027, the company’s internal handling of Annex XIV, Annex XVII and SVHC substances is to be reviewed. [more]

Comments are closed.